Table 1:

Summary of FDA approved TKI for advanced GIST

FDA APPROVED TKI	YEAR OF INITIAL FDA APPROVAL	INDICATION
IMATINIB	2002	Malignant metastatic and/or unresectable GISTs
SUNITINIB	2006	Imatinib refractory or intolerant locally advanced GISTs
REGORAFENIB	2013	Advanced GIST previously treated with imatinib and sunitinib
AVAPRITINIB	2020	Advanced GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutation
RIPRETINIB	2020	Advanced GIST who have received 3 or more prior TKIs including imatinib

Source: FDA Approval Dates

Abbreviations: FDA: Food and Drug Administration; GIST: Gastrointestinal Stromal Tumor; PDGFRA: platelet derived growth factor alpha; TKI: Tyrosine Kinase Inhibitor